Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development

ObjectiveTo use a stochastic model to gain insights into the consequence for resistance development of different drug use patterns. MethodsWe consider use of three drugs (A, B and C) where for each drug one and only one viral mutation is associated with ability to replicate (effective reproductive ratio, R > 1) in the presence of that drug as monotherapy. For drug A mutation is a, etc. We define eight populations of short-lived infected cells that live 1 day: Vo with no mutations a, b, c; Va with mutation a only, Vab with mutations a and b, etc. A random number generator was used to determine whether mutations occur in any one round of replication and to sample from a Poisson distribution to determine for each cell the number of cells of the same population created in the next generation, using the R operative at that time. Values of R depended on drug exposure, cost of resistance and availability of target cells. ResultsTreatment strategies and the resulting percentage (over 100 runs) developing full ‘resistance’ in 1500 days (Vabc ≠ 0) were: (i) ABC 1500 days 0%; (ii) A 300 days, AB 300 days, ABC 900 days 100%; (iii) AB 300 days, ABC 1200 days 33%; (iv) ABC 2/3 1500 days 15%; (v) ABC 1/2 1500 days 100%; (vi) ABC 50 days, no drugs 50 days, for 1500 days 1%, where ABC 2/3 means on-drug for 2 days in every 3, ABC 1/2 represents on-drug for 1 day in every 2, and represents suboptimal adherence. ConclusionsThis model helps to develop understanding of key principles concerning development of resistance under different patterns of treatment use.

[1]  A. Phillips,et al.  In vivo HIV-1 replicative capacity in early and advanced infection. , 1999, AIDS.

[2]  R. Siliciano,et al.  Viral Dynamics in HIV-1 Infection , 1998, Cell.

[3]  G. M. Ortiz,et al.  Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection , 2000, AIDS.

[4]  M. Youle,et al.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.

[5]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[6]  L. M. Mansky,et al.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase , 1995, Journal of virology.

[7]  A. Perelson,et al.  Dynamics of HIV infection of CD4+ T cells. , 1993, Mathematical biosciences.

[8]  J. Coffin,et al.  Linkage disequilibrium test implies a large effective population number for HIV in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Leitner,et al.  Stochastic processes strongly influence HIV-1 evolution during suboptimal protease-inhibitor therapy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  A. J. Brown,et al.  Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Sebastian Bonhoeffera,et al.  Risks and bene®ts of structured antiretroviral drug therapy interruptions in HIV-1 infection , 2022 .

[13]  D Schenzle,et al.  A model for AIDS pathogenesis. , 1994, Statistics in medicine.

[14]  B Clotet,et al.  Prospective Randomized Two‐Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long‐Term Adherence to Highly Active Antiretroviral Therapy , 2000, Journal of acquired immune deficiency syndromes.

[15]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[16]  S. Friedman,et al.  HIV infection among intravenous drug users: epidemiology and risk reduction. , 1987, AIDS.

[17]  P D Griffiths,et al.  Population dynamics of HIV within an individual after treatment with zidovudine , 1991, AIDS.

[18]  A S Perelson,et al.  Modeling HIV infection of CD4+ T-cell subpopulations. , 1994, Journal of theoretical biology.

[19]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[20]  Alan S. Perelson,et al.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy , 2000, Nature Medicine.

[21]  G. F. Webb,et al.  Understanding drug resistance for monotherapy treatment of HIV infection , 1997, Bulletin of mathematical biology.

[22]  M A Nowak,et al.  Competition between zidovudine‐sensitive and zidovudine‐resistant strains of HIV , 1992, AIDS.

[23]  D. Richman,et al.  HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.

[24]  L M Wahl,et al.  Adherence and drug resistance: predictions for therapy outcome , 2000, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[25]  S Bonhoeffer,et al.  Production of resistant HIV mutants during antiretroviral therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[27]  D. Richman,et al.  Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.

[28]  Martin A. Nowak,et al.  The frequency of resistant mutant virus before antiviral therapy , 1998, AIDS.

[29]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[30]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[31]  C. Boucher,et al.  Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model , 1997, Journal of virology.

[32]  A. Phillips HIV Dynamics: Lessons from the use of antiretrovirals , 1999 .

[33]  K. Lange,et al.  Mutation Takes No Vacation: Can Structured Treatment Interruptions Increase the Risk of Drug‐Resistant HIV‐1? , 2000, Journal of acquired immune deficiency syndromes.

[34]  Alan S. Perelson,et al.  Quantitative Image Analysis of HIV-1 Infection in Lymphoid Tissue , 1996, Science.

[35]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[36]  P. Kaye Infectious diseases of humans: Dynamics and control , 1993 .

[37]  R. Paredes,et al.  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression , 2000, AIDS.

[38]  D. Richman,et al.  HIV-1: Gambling on the evolution of drug resistance? , 1997, Nature Medicine.

[39]  S. Wain-Hobson HIV genome variability in vivo , 1989, AIDS.

[40]  A S Perelson,et al.  Drug concentration heterogeneity facilitates the evolution of drug resistance. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Zupancic,et al.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. , 1997, Science.

[42]  A. McLean,et al.  HIV‐1 dynamics after transient antiretroviral therapy: Implications for pathogenesis and clinical management , 1997, Journal of medical virology.